Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.80 |
| ▸ | CTSV | O60911 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468570 | 0.89 | DHODH (0.64) | DHODHCTSVCTSLMEN1KMT2A | |
| SCHEMBL468580 | 0.89 | DHODH (0.82) | DHODH | |
| SCHEMBL468466 | 0.89 | DHODH (1.00) | DHODH | |
| SCHEMBL468533 | 0.88 | DHODH (0.80) | DHODHMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13951324 | 0.88 | DHODH (0.80) | DHODHRXRARXRB | |
| SCHEMBL468552 | 0.88 | DHODH (0.80) | DHODH | |
| SCHEMBL468440 | 0.84 | DHODH (0.81) | DHODHCTSVCTSLMEN1NPC1 | |
| SCHEMBL4483532 | 0.84 | CTSV (0.74) | DHODHCTSVCTSLMEN1NPC1 | |
| SCHEMBL468774 | 0.83 | DHODH (0.82) | DHODHCTSVCTSL | |
| SCHEMBL2825608 | 0.83 | DHODH (0.73) | DHODHMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | claimed |
| EP-2178840-B1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2011-12-14 | — | — | EP | claimed |
| EP-2389197-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | Almirall S.A. (ES) | 2011-11-30 | — | — | EP | claimed |
| US-20110280831-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-11-17 | — | — | US | claimed |
| US-20110253957-A1 | Compliant motion distribution system | FLEXSYS, INC. | 2011-10-20 | — | — | US | claimed |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-09-01 | — | — | US | claimed |
| WO-2010083975-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2010-07-29 | — | — | WO | claimed |
| EP-2210615-A1 | Combinations comprising methotrexate and DHODH inhibitors | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | claimed |
| EP-2178840-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2010-04-28 | — | — | EP | claimed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | claimed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | claimed |
| EP-2389197-B1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL SA (ES) | 2014-06-18 | — | — | EP | disclosed |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| US-8536165-B2 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | ALMIRALL, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| US-8536165-B2 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | ALMIRALL, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-2178840-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2010-04-28 | — | — | EP | disclosed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280831-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | DHODH, CBR3, HRH4 | DHODH 1/4885CTSV 4008/4885CTSL 2974/4885 |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | DHODH 1/4885CTSV 3770/4885CTSL 3114/4885 |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | DHODH 1/4885CTSV 3770/4885CTSL 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.